SLIT-ROBO Rho GTPase-activating protein 2C (SRGAP2C)

ENSG00000308561, described here as "novel transcript, antisense to SRGAP2C," does not correspond to a canonical, protein-coding pharmacological or therapeutic target such as a receptor, enzyme, transporter, or transcription factor. Instead, SRGAP2C is a human-specific rearranged paralog (copy) of the ancestral SRGAP2A gene, generated by partial gene duplication and mutation. Unlike canonical receptors or enzymes, SRGAP2C is not a classical drug target, nor is there clinical evidence of interacting drugs or direct disease targeting. The SRGAP2C protein acts mainly through inhibition of its ancestral paralog SRGAP2A—which is involved in the regulation of synaptic maturation and neuronal migration in the developing cortex—by heterodimerizing with it and interfering with its function. This inhibition delays synaptic maturation and increases synaptic density, mimicking aspects observed in human brain evolution[1][2][4][6][9]. SRGAP2C is highly specific to humans and thought to contribute to human-specific features of brain connectivity and cortical development; its expression pattern and function are primarily studied in evolutionary neurobiology rather than clinical disease models or drug development. There is no evidence for therapeutic modulation of SRGAP2C, nor for its classification as a traditional drug target. **Note on antisense transcript:** The entity labeled as "novel transcript, antisense to SRGAP2C" (ENSG00000308561) is, according to major scientific databases, likely an uncharacterized or predicted non-coding transcript antisense to the SRGAP2C locus, not a canonical, druggable target. No evidence exists for this transcript being a receptor, enzyme, transporter, or traditional target molecule[8][9]. This makes it *not* a standard therapeutic target and thus flagged as *incorrect* for most biomedical target databases. **Summary:** - ENSG00000308561 is not a classical or validated therapeutic target. - SRGAP2C is a synaptic regulatory protein, important in human neurodevelopment. - There are no known drugs, established mechanisms of drug action, or clinical biomarkers associated with SRGAP2C or its antisense transcript. - The antisense transcript is not well characterized, not a protein, and not a target. **References:** Direct statements above are supported by primary literature and reputable gene/protein databases[1][2][4][5][6][7][9]. The antisense transcript status is confirmed with reference to HGNC and UniProt[8][9].

Other names

SRGAP2CProtein FAM72E (obsolete)human-specific paralog of SRGAP2